HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $25.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 236.47% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. The Goldman Sachs Group reduced their target price on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday. StockNews.com raised shares of uniQure to a “sell” rating in a research report on Thursday, October 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $28.00 price target on shares of uniQure in a report on Wednesday. Royal Bank of Canada cut their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Raymond James reaffirmed an “outperform” rating and issued a $20.00 price target on shares of uniQure in a report on Thursday, October 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $17.00.

uniQure Trading Up 3.8 %

NASDAQ QURE opened at $7.43 on Wednesday. The company’s fifty day simple moving average is $5.73 and its 200-day simple moving average is $5.80. uniQure has a 52 week low of $3.73 and a 52 week high of $11.35. The company has a current ratio of 7.36, a quick ratio of 7.36 and a debt-to-equity ratio of 1.06. The stock has a market cap of $361.84 million, a P/E ratio of -1.25 and a beta of 0.90.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. uniQure had a negative net margin of 1,027.52% and a negative return on equity of 158.09%. The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. Equities research analysts predict that uniQure will post -4.1 EPS for the current fiscal year.

Institutional Investors Weigh In On uniQure

Several institutional investors and hedge funds have recently bought and sold shares of the business. abrdn plc boosted its stake in uniQure by 381.7% in the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after acquiring an additional 1,528,581 shares during the period. Vanguard Group Inc. boosted its position in uniQure by 11.4% during the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock valued at $5,577,000 after purchasing an additional 109,740 shares during the period. Privium Fund Management B.V. grew its stake in uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after buying an additional 104,500 shares during the last quarter. BNP Paribas Financial Markets increased its position in uniQure by 4.3% in the first quarter. BNP Paribas Financial Markets now owns 736,724 shares of the biotechnology company’s stock worth $3,831,000 after buying an additional 30,054 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in uniQure by 133.1% in the first quarter. Acadian Asset Management LLC now owns 613,490 shares of the biotechnology company’s stock valued at $3,189,000 after buying an additional 350,291 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.